Skip to main content
PMC home page
Annals of Surgery logoLink to Annals of Surgery
. 1995 Jun;221(6):685–695. doi: 10.1097/00000658-199506000-00008

Downstaging of esophageal cancer after preoperative radiation and chemotherapy.

S B Vogel 1, W M Mendenhall 1, M D Sombeck 1, R Marsh 1, E R Woodward 1
PMCID: PMC1234696  PMID: 7794073

Abstract

OBJECTIVE: This retrospective, nonrandomized review evaluates 125 patients with esophageal carcinoma (adenocarcinoma and squamous cell) who underwent either surgery only or preoperative chemotherapy and/or radiation therapy followed by surgery. Major end points were survival and postchemoradiation downstaging. METHODS: Forty-four patients underwent radiation therapy of 4500 cGy over 5 weeks. Fluorouracil and cisplatin were administered on the first and fifth week of radiotherapy. Ninety-eight patients underwent "potentially curative" resections-transhiatal esophagectomy (70), Lewis esophagogastrectomy (25), and left esophagogastrectomy (3). All patients with preoperative adjuvant therapy underwent endoscopy and biopsy before surgery. RESULTS: There were no differences in overall mortality (5%) or surgical complications in either group. Fourteen of 44 patients (32%) downstaged to complete pathologic response, with 5-year survival of 57%. Fifteen of 44 patients (34%) downstaged to microscopic residual tumor, with 1- and 3-year survival of 77% and 31%, respectively. Twenty-eight of 29 patients in the two downstaged groups were lymph node negative. Overall, 5-year survival in the adjuvant therapy plus surgery group versus surgery only was 36% and 11% (p = 0.04). Five-year survival in lymph node-negative adjuvant therapy and surgery patients was 49% (p = 0.005). Positive nodes in the surgery only group was 48% versus 23% in the adjuvant therapy and surgery group (p = 0.02). CONCLUSION: Although retrospective and nonrandomized, these results suggest that preoperative chemoradiation results in significant clinical and pathologic downstaging, increases survival, and may sterilize local and regional lymph nodes, accounting for both downstaging and survival statistics.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ajani J. A., Roth J. A., Ryan B., McMurtrey M., Rich T. A., Jackson D. E., Abbruzzese J. L., Levin B., DeCaro L., Mountain C. Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol. 1990 Jul;8(7):1231–1238. doi: 10.1200/JCO.1990.8.7.1231. [DOI] [PubMed] [Google Scholar]
  2. Blot W. J. Esophageal cancer trends and risk factors. Semin Oncol. 1994 Aug;21(4):403–410. [PubMed] [Google Scholar]
  3. Boring C. C., Squires T. S., Tong T. Cancer statistics, 1993. CA Cancer J Clin. 1993 Jan-Feb;43(1):7–26. doi: 10.3322/canjclin.43.1.7. [DOI] [PubMed] [Google Scholar]
  4. Coia L. R. Chemoradiation as primary management of esophageal cancer. Semin Oncol. 1994 Aug;21(4):483–492. [PubMed] [Google Scholar]
  5. Coia L. R., Engstrom P. F., Paul A. R., Stafford P. M., Hanks G. E. Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. Int J Radiat Oncol Biol Phys. 1991 Jan;20(1):29–36. doi: 10.1016/0360-3016(91)90134-p. [DOI] [PubMed] [Google Scholar]
  6. Coia L. R., Paul A. R., Engstrom P. F. Combined radiation and chemotherapy as primary management of adenocarcinoma of the esophagus and gastroesophageal junction. Cancer. 1988 Feb 15;61(4):643–649. doi: 10.1002/1097-0142(19880215)61:4<643::aid-cncr2820610404>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  7. Forastiere A. A., Orringer M. B., Perez-Tamayo C., Urba S. G., Husted S., Takasugi B. J., Zahurak M. Concurrent chemotherapy and radiation therapy followed by transhiatal esophagectomy for local-regional cancer of the esophagus. J Clin Oncol. 1990 Jan;8(1):119–127. doi: 10.1200/JCO.1990.8.1.119. [DOI] [PubMed] [Google Scholar]
  8. Forastiere A. A., Orringer M. B., Perez-Tamayo C., Urba S. G., Zahurak M. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. J Clin Oncol. 1993 Jun;11(6):1118–1123. doi: 10.1200/JCO.1993.11.6.1118. [DOI] [PubMed] [Google Scholar]
  9. Franklin R., Steiger Z., Vaishampayan G., Asfaw I., Rosenberg J., Loh J., Hoschner J., Miller P. Combined modality therapy for esophageal squamous cell carcinoma. Cancer. 1983 Mar 15;51(6):1062–1071. doi: 10.1002/1097-0142(19830315)51:6<1062::aid-cncr2820510615>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  10. Gill P. G., Denham J. W., Jamieson G. G., Devitt P. G., Yeoh E., Olweny C. Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery . J Clin Oncol. 1992 Jul;10(7):1037–1043. doi: 10.1200/JCO.1992.10.7.1037. [DOI] [PubMed] [Google Scholar]
  11. Herskovic A., Martz K., al-Sarraf M., Leichman L., Brindle J., Vaitkevicius V., Cooper J., Byhardt R., Davis L., Emami B. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992 Jun 11;326(24):1593–1598. doi: 10.1056/NEJM199206113262403. [DOI] [PubMed] [Google Scholar]
  12. Ilson D. H., Kelsen D. P. Combined modality therapy in the treatment of esophageal cancer. Semin Oncol. 1994 Aug;21(4):493–507. [PubMed] [Google Scholar]
  13. Leichman L., Herskovic A., Leichman C. G., Lattin P. B., Steiger Z., Tapazoglou E., Rosenberg J. C., Arbulu A., Asfaw I., Kinzie J. Nonoperative therapy for squamous-cell cancer of the esophagus. J Clin Oncol. 1987 Mar;5(3):365–370. doi: 10.1200/JCO.1987.5.3.365. [DOI] [PubMed] [Google Scholar]
  14. Leichman L., Steiger Z., Seydel H. G., Dindogru A., Kinzie J., Toben S., MacKenzie G., Shell J. Preoperative chemotherapy and radiation therapy for patients with cancer of the esophagus: a potentially curative approach. J Clin Oncol. 1984 Feb;2(2):75–79. doi: 10.1200/JCO.1984.2.2.75. [DOI] [PubMed] [Google Scholar]
  15. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Sauter E. R., Coia L. R., Keller S. M. Preoperative high-dose radiation and chemotherapy in adenocarcinoma of the esophagus and esophagogastric junction. Ann Surg Oncol. 1994 Jan;1(1):5–10. doi: 10.1007/BF02303535. [DOI] [PubMed] [Google Scholar]
  17. Smalley S. R., Gunderson L. L., Reddy E. K., Williamson S. Radiotherapy alone in esophageal carcinoma: current management and future directions of adjuvant, curative and palliative approaches. Semin Oncol. 1994 Aug;21(4):467–473. [PubMed] [Google Scholar]
  18. Stewart F. M., Harkins B. J., Hahn S. S., Daniel T. M. Cisplatin, 5-fluorouracil, mitomycin C, and concurrent radiation therapy with and without esophogectomy for esophageal carcinoma. Cancer. 1989 Aug 1;64(3):622–628. doi: 10.1002/1097-0142(19890801)64:3<622::aid-cncr2820640310>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  19. Sun D. R. Ten-year follow-up of esophageal cancer treated by radical radiation therapy: analysis of 869 patients. Int J Radiat Oncol Biol Phys. 1989 Feb;16(2):329–334. [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES